Drug trial halted for rare brain tumor condition
NCT ID NCT05130866
Summary
This study tested an investigational drug called REC-2282 to see if it could slow or stop the growth of brain tumors (meningiomas) in people with Neurofibromatosis Type 2 (NF2). It involved about 25 participants aged 12 and older with progressive tumors. The trial was designed in two parts: first to find a safe dose, and then to compare the drug's effectiveness against a placebo, but the study was terminated early.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROFIBROMATOSIS TYPE 2 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
-
Children's National Hospital
Washington D.C., District of Columbia, 20010, United States
-
Columbia University
New York, New York, 10032, United States
-
Duke University Medical Center
Durham, North Carolina, 27710, United States
-
House Institute
Los Angeles, California, 90057, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Mayo Clinic
Rochester, Minnesota, 55905, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Nicklaus Children's Hospital
Miami, Florida, 33155, United States
-
Sarah Cannon Cancer Institute - HCA Midwest
Overland Park, Kansas, 66211, United States
-
UT Southwestern Medical Center
Dallas, Texas, 75390, United States
-
University of California Los Angeles
Los Angeles, California, 90095, United States
-
University of Florida
Gainesville, Florida, 32611, United States
-
University of Minnesota / Masonic Cancer Center
Minneapolis, Minnesota, 55455, United States
Conditions
Explore the condition pages connected to this study.